|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/26/20 OncoCyte Corp 10-K 12/31/19 77:37M M2 Compliance/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 697K
2: EX-4.11 Instrument Defining the Rights of Security Holders HTML 24K
3: EX-10.10 Material Contract HTML 31K
4: EX-10.24 Material Contract HTML 32K
5: EX-10.34 Material Contract HTML 35K
6: EX-10.35 Material Contract HTML 50K
7: EX-10.36 Material Contract HTML 97K
8: EX-21 Subsidiaries List HTML 22K
9: EX-23.1 Consent of Experts or Counsel HTML 24K
10: EX-31 Certification -- §302 - SOA'02 HTML 37K
11: EX-32 Certification -- §906 - SOA'02 HTML 25K
23: R1 Document and Entity Information HTML 61K
60: R2 Balance Sheets HTML 97K
67: R3 Balance Sheets (Parenthetical) HTML 43K
49: R4 Statements of Operations HTML 63K
24: R5 Statements of Comprehensive Loss HTML 35K
61: R6 Statements of Shareholders' Equity HTML 66K
68: R7 Statements of Cash Flows HTML 133K
47: R8 Organization, Description of the Business and HTML 37K
Liquidity
26: R9 Summary of Significant Accounting Policies HTML 80K
58: R10 Selected Balance Sheet Components HTML 41K
70: R11 Related Party Transactions HTML 40K
46: R12 Equity Method Investment in Razor Genomics, Inc. HTML 45K
25: R13 Loan Payable to Silicon Valley Bank HTML 44K
59: R14 Shareholders' Equity HTML 32K
71: R15 Stock-Based Compensation HTML 72K
48: R16 Income Taxes HTML 50K
27: R17 Commitments and Contingencies HTML 66K
62: R18 Subsequent Events HTML 35K
69: R19 Summary of Significant Accounting Policies HTML 136K
(Policies)
35: R20 Summary of Significant Accounting Policies HTML 34K
(Tables)
28: R21 Selected Balance Sheet Components (Tables) HTML 47K
52: R22 Related Party Transactions (Tables) HTML 28K
74: R23 Equity Method Investment in Razor Genomics, Inc. HTML 29K
(Tables)
36: R24 Loan Payable to Silicon Valley Bank (Tables) HTML 29K
29: R25 Stock-Based Compensation (Tables) HTML 70K
53: R26 Income Taxes (Tables) HTML 47K
75: R27 Commitments and Contingencies (Tables) HTML 44K
34: R28 Organization, Description of the Business and HTML 52K
Liquidity (Details Narrative)
30: R29 Summary of Significant Accounting Policies HTML 81K
(Details Narrative)
22: R30 Summary of Significant Accounting Policies - HTML 33K
Schedule of Reconciliation of Cash, Cash
Equivalents, and Restricted Cash (Details)
44: R31 Summary of Significant Accounting Policies - HTML 31K
Common Stock Equivalents Excluded from Computation
of Diluted Net Loss Per Share of Common Stock
(Details)
73: R32 Selected Balance Sheet Components (Details HTML 32K
Narrative)
64: R33 Selected Balance Sheet Components - Schedule of HTML 34K
Prepaid Expenses and Other Current Assets
(Details)
21: R34 Selected Balance Sheet Components - Schedule of HTML 31K
Deposits and Other Noncurrent Assets (Details)
43: R35 Selected Balance Sheet Components - Schedule of HTML 30K
Accrued Expenses and Other Current Liabilities
(Details)
72: R36 Selected Balance Sheet Components - Schedule of HTML 36K
Right of Use Assets, Machinery and Equipment, Net
(Details)
63: R37 Related Party Transactions (Details Narrative) HTML 99K
20: R38 Related Party Transactions - Schedule of Aggregate HTML 36K
Use of Fees Charged (Details)
45: R39 Equity Method Investment in Razor Genomics, Inc. HTML 80K
(Details Narrative)
33: R40 Equity Method Investment in Razor Genomics, Inc. - HTML 53K
Schedule of Condensed Balance Sheet Information
(Details)
39: R41 Loan Payable to Silicon Valley Bank (Details HTML 106K
Narrative)
77: R42 Loan Payable to Silicon Valley Bank - Schedule of HTML 45K
Future Cash Payments of Loan Payable (Details)
55: R43 Shareholders' Equity (Details Narrative) HTML 62K
32: R44 Stock-Based Compensation (Details Narrative) HTML 76K
38: R45 Stock-Based Compensation - Summary of Stock Option HTML 90K
Activity (Details)
76: R46 Stock-Based Compensation - Schdule of Stock HTML 46K
Options Outstanding, Vested and Exercisable
(Details)
54: R47 Stock-Based Compensation - Summary of Stock-based HTML 31K
Compensation Expense (Details)
31: R48 Stock-Based Compensation - Schedule of Assumptions HTML 35K
Used to Calculate Fair Value of Stock Options
(Details)
40: R49 Income Taxes (Details Narrative) HTML 55K
41: R50 Income Taxes - Schedule of Components of Deferred HTML 50K
Tax Assets and Liabilities (Details)
18: R51 Income Taxes - Schedule of Income Tax HTML 49K
Reconciliation (Details)
56: R52 Income Taxes - Schedule of Unrecognized Tax HTML 31K
Benefit (Details)
65: R53 Commitments and Contingencies (Details Narrative) HTML 67K
42: R54 Commitments and Contingencies - Schedule of HTML 31K
Supplemental Cash Flow Information Related to
Operating and Financing Lease (Details)
19: R55 Commitments and Contingencies - Schedule of HTML 45K
Supplemental Balance Sheet Information Related to
Operating and Financing Leases (Details)
57: R56 Commitments and Contingencies - Schedule of Future HTML 70K
Minimum Lease Commitments for Operating and
Financing Leases (Details)
66: R57 Subsequent Events (Details Narrative) HTML 71K
37: XML IDEA XML File -- Filing Summary XML 131K
50: EXCEL IDEA Workbook of Financial Reports XLSX 96K
12: EX-101.INS XBRL Instance -- ocx-20191231 XML 1.15M
14: EX-101.CAL XBRL Calculations -- ocx-20191231_cal XML 197K
15: EX-101.DEF XBRL Definitions -- ocx-20191231_def XML 614K
16: EX-101.LAB XBRL Labels -- ocx-20191231_lab XML 1.15M
17: EX-101.PRE XBRL Presentations -- ocx-20191231_pre XML 855K
13: EX-101.SCH XBRL Schema -- ocx-20191231 XSD 194K
51: ZIP XBRL Zipped Folder -- 0001493152-20-004738-xbrl Zip 166K
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of OncoCyte Corporation (the “Company”) for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Ronald Andrews, President and Chief Executive Officer, and Mitchell Levine, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 25, 2020
| /s/ Ronald Andrews | |
| Ronald Andrews | |
| President and Chief Executive Officer | |
| /s/ Mitchell Levine | |
| Mitchell Levine | |
| Chief Financial Officer |
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 3/26/20 | |||
| Filed on: | 3/25/20 | 8-K | ||
| For Period end: | 12/31/19 | 10-K/A | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/16/24 Oncocyte Corp. 10-K 12/31/23 87:30M M2 Compliance LLC/FA 4/12/23 Oncocyte Corp. 10-K 12/31/22 94:11M M2 Compliance LLC/FA 5/02/22 Oncocyte Corp. 10-K/A 12/31/21 12:649K M2 Compliance LLC/FA 3/11/22 Oncocyte Corp. 10-K 12/31/21 90:10M M2 Compliance LLC/FA 4/30/21 OncoCyte Corp. 10-K/A 12/31/20 2:488K M2 Compliance LLC/FA 3/19/21 OncoCyte Corp. 10-K 12/31/20 93:7.4M M2 Compliance LLC/FA |